To examine the gap between evidence-based indications for PSMA PET/CT and real-world access in prostate cancer, with a focus on European implementation and country-specific experience from Spain and France. A focused narrative appraisal of published evidence, clinical guidelines, regulatory and reimbursement informatio...
J. G. Rivas, L. F. Hernández, L. Turpin et al.· World journal of urology· 0 citations
Improving access to high-quality PSMA PET should be regarded not only as a logistical objective but also as a clinical priority to ensure that advances in molecular imaging translate into more precise, timely, and equitable PCa care.
A. Peyrottes, L. Turpin, L. F. Hernández et al.· European Urology Oncology· 2 citations
Growing evidence suggests that AS appears oncologically safe in well-selected patients, and magnetic resonance imaging will play a key role in the appropriate selection and follow-up of patients.
Alessandro Uleri, L. Cella, T. Long-Depaquit et al.· BJU International· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.